Keith A. Webster, BA, Ph.D., FAHA
Founder, CEO and President

Dr. Webster is currently Professor of Pharmacology, Director of the Vascular Biology Institute, and Walter G. Ross Distinguished Chair of Vascular Biology at the University of Miami Miller School of Medicine He is also Scientific Advisor and co-Founder of Miami Cardiovascular Innovations, a privately owned company engaged in the development of devices and biotechnology for cardiovascular medicine.  Dr. Webster described the first formulation and use of a novel hypoxia-responsive gene switch in 1997 during his work as Director of the Molecular Cardiology Laboratories at SRI International, Menlo Park, California.  The current proprietary switch formulation was developed and tested at the University of Miami.  Dr. Webster obtained his B.A., and Ph.D. degrees from the University of York, UK, and holds honorary professorships at St. Luke's Hospital, Manila, Philippines and Zhejiang University, Hangzhou, China.  He has published more than 150 articles related to the molecular biology of hypoxia and ischemia,  and vascular biology in cancer and cardiovascular disease including hypoxia-targeted gene therapy.

Jim DeMesa, MD, MBA

Business Advisor

Dr. DeMesa has been a practicing physician and has served as a senior executive with several international pharmaceutical and biotech companies, both public and private, in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Dr. DeMessa serves on the Board of Directors of Induce Biologics, a regenerative medicine company and OncoSec Medical, a cancer company. In 2008, Dr. DeMesa retired from his role as President, Chief Executive Officer and a director of Migenix Inc., a public biotechnology company focused on infectious and neurodegenerative diseases. From 1997 to 2001, he was President, Chief Executive Officer and a director of GenSci Regeneration Sciences Inc., a public biotech company involved in regenerative medicine (now part of Integra LifeSciences, NASD: IART). During his tenure at these two companies, Dr. DeMesa led the acquisition of several technologies and companies and completed multiple strategic partnership transactions with companies such as J&J, Astellas Pharmaceuticals, United Therapeutics, and Cadence Pharmaceuticals. He also led multiple successful financings totaling over $150 million. From 1992 to 1997, he was Vice President, Medical and Regulatory Affairs at Biodynamics International, Inc. (now part of RTI Surgical, NASD: RTIX), and from 1989 to 1992 was Vice President, Medical and Regulatory Affairs at Bentley Pharmaceuticals (now part of Teva Pharmaceuticals, NYSE: TEVA). Dr. DeMesa is a co-founder of CommGeniX, a medical communications company, and MedXcel, a medical education company. Dr. DeMesa attended the University of South Florida where he received his B.A. (Chemistry), M.D. and M.B.A. degrees and did his medical residency at the University of North Carolina.

Associate Advisors:
Nancy Coulson, MBA: Regulatory Affairs
Ms. Coulson has spent three decades in the regulatory arena working on multiple device, biologic, and tissue-based products with Johnson & Johnson, GenSci Regeneration Sciences, Bristol-Myers Squibb, Baush  & Lomb, and Migenix.

David Greenspan, PhD: Product Development
Dr. Greenspan is an experienced product development and quality systems expert, with over 32 years of experience in the medical device industry.  He has been responsible for taking several products from concept to market and has extensive experience in the areas of design control, regulatory processes, and project management.

Clinical Advisory Board Member
Dr. Murray Shames, 
Professor of Surgery and Radiology and Program Director of Vascular Surgery, Division of Vascular and Endovascular Surgery USF Health Morsani School of Medicine.

Dr. Paul A. Kurlansky, Specialist in Cardiothoracic and General Surgery, Associate Professor, Division of Surgery, Columbia University, New York

Board Members:

Michael Gold,  Executive Chairman
Mr. Gold has a long career in corporate development in the US. He is currently Chairman and co-founder of Events International Network LLC  a  media,  marketing, and advertising company with offices in Miami and New York and London.

Marvin Sackner MD.
Dr. Sackner was the former Chief of Medicine Mount Sinai Hospital Miami Beach Florida . He was the CEO of Non Invasive Monitoring Systems, Miami Florida, and Vice Chairman of the board of Continucare Corporation Miami Florida.



The Future of 
Vascular Bio-Technology


Website Builder